GEO DataSets

(Submitter supplied) CD38 expression is an important prognostic marker in CLL with high levels of CD38 associated with shorter overall survival. In this study, we used gene expression profiling and protein analysis of highly purified cell-sorted CD38+ and CD38- chronic lymphocytic leukemia cells to elucidate a molecular basis for the association between CD38 expression and inferior clinical outcome. Paired CD38+ and CD38- CLL cells derived from the same patient were shown to be monoclonal by VH gene sequencing but despite this, CD38+ CLL cells possessed a distinct gene expression profile when compared with their CD38- sub-clones. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS2676

Platform:

GPL571

12 Samples

Download data: CEL

Analysis of paired CD38(+) and CD38(-) chronic lymphocytic leukemia (CLL) cells from six patients. CD38 expression is an important prognostic marker in CLL with high levels of CD38 antigen associated with shorter overall survival. Results provide insight into the molecular basis of this association.

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 2 cell type, 6 individual sets

Platform:

GPL571

Series:

GSE6321

12 Samples

Download data: CEL

(Submitter supplied) B-cell chronic lymphocytic leukemia (B-CLL) is a heterogenous disease with a highly variable clinical course and analysis of ZAP-70 and CD38 expression on B-CLL cells allowed for identification of patients with good (ZAP-70-CD38-), intermediate (discordant expression of ZAP-70 and CD38) and poor (ZAP-70+CD38+) prognosis. In an attempt to identify a molecular basis that may underly this diverse clinical behaviour DNA microarray technology was employed to compare eight ZAP-70+CD38+ with eight ZAP-70-CD38- B-CLL cases. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS2501

Platform:

GPL96

16 Samples

Download data

Analysis of B-cell chronic lymphocytic leukemia (B-CLL) cells that express or do not express zeta-associated protein (ZAP-70) and CD38. The prognosis of patients with ZAP-70-CD38- B-CLL cells is good, those with ZAP-70+CD38+ B-CLL cells is poor.

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 2 cell type, 2 other sets

Platform:

GPL96

Series:

GSE4392

16 Samples

Download data

(Submitter supplied) Recent data indicate that CD38, a cell surface enzyme and receptor, is part of the complex network of signals underlying the development, maintenance and progression of chronic lymphocytic leukemia (CLL). Here we show that CD38 signals directly facilitate short- (ERK1/2 phosphorylation) and long-term (chemotaxis) effects induced by CXCL12 exposure. Use of i) a specific enzyme inhibitor, ii) an agonistic anti-CD38 monoclonal antibody (mAb) and iii) microarray studies led to the conclusion that the receptor-like functions of CD38 are responsible for the observed effects. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL1708

30 Samples

Download data: TXT

(Submitter supplied) This work shows that signaling-lymphocytic-activation-molecule-1 (SLAMF1), a co-stimulatory molecule and a microbial sensor, is expressed by normal CD19+/CD5+ B-lymphocytes. Its expression is lost in a subset of patients with chronic lymphocytic leukemia (CLL) characterized by an aggressive form of the disease, with shorter time to first treatment and overall survival. Silencing of SLAMF1 in the CLL-like Mec-1 cell line (constitutively SLAMF1+) modulated pathways connected to cell migration, cytoskeletal organization and intracellular vesicle formation/recirculation. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL10558

6 Samples

Download data: TXT

(Submitter supplied) Purpose: Accurate prediction of clinical response is the prerequisite for individualized therapy in chronic lymphocytic leukemia (CLL). We hypothesized that sequential assessment of gene expression changes early during therapy may well reflect behaviour of the leukemic clone in response to specific drugs. Patients and Methods: Gene expression profiles (GEP) were determined in CD19+ selected B-cells from 20 patients treated with fludarabine and cyclophosphamide (FC) (N=10) or FC plus rituximab (FCR) (N=10). more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS3829

Platform:

GPL570

50 Samples

Download data: CEL

Analysis of CD19+ selected B cells from CLL patients before and after chemoimmunotherapy regimens of rituximab (R), fludarabine and cyclophosphamide (FC), or RFC. Results provide insight into the molecular mechanisms underlying the beneficial effects of the chemoimmunotherapy regimens.

Organism:

Homo sapiens

Type:

Expression profiling by array, transformed count, 5 agent sets

Platform:

GPL570

Series:

GSE15490

50 Samples

Download data: CEL

(Submitter supplied) Distinct genetic abnormalities such as TP53 deletion at 17p13.1, have been identified as having an adverse prognostic relevance in B-cell chronic lymphocytic leukemia (B-CLL). Conventional cytogenetic studies have shown that TP53 deletion in B-CLL is associated predominantly with 17p loss resulting from complex chromosomal rearrangements. We performed genome-wide DNA (SNPs arrays), fluorescence in situ hybridization (FISH) and gene expression profiling (GEP) analyses to investigate the significance of 17p loss in a panel of 71 genetically well-characterized B-CLLs in Binet stage A, 18 of which carried a TP53 monoallelic deletion. more...

Organism:

Homo sapiens

Type:

Expression profiling by array; Genome variation profiling by SNP array

Platforms:

GPL2005 GPL96

72 Samples

Download data: CEL